Medical Oncologist
After surgery · EGFR-positive lung cancer
Adjuvant Osimertinib After Lung Surgery — Three Years to Reduce Recurrence Risk
Your surgery removed the tumour. Adjuvant osimertinib is the next step — a daily tablet for three years intended to reduce the chance that any remaining microscopic cancer cells grow back. It is a different use of this drug from what you may have read about for advanced lung cancer.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Surgery is step one, not the last step — Osimertinib addresses what surgery cannot see — microscopic cells that may remain even after a technically successful operation.
- Different from advanced-stage treatment — The same drug treats metastatic lung cancer for different reasons. Confusing the two settings is common, and this page explains the distinction.
- Three years of daily tablets — One tablet once a day, every day, for 36 months. Consistent daily use is what the evidence is based on.
- Only for specific EGFR mutations — Your pathology report must confirm an exon 19 deletion or exon 21 L858R mutation. Not every EGFR-positive result qualifies.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Adjuvant osimertinib is a daily tablet taken for three years after surgery for EGFR-mutated non-small cell lung cancer. It differs from osimertinib used in advanced disease — here, the aim is to reduce the chance your cancer returns, not to treat spread. NCCN and ASCO both recommend it for eligible early-stage patients.
Is this the same osimertinib used for advanced lung cancer?
Osimertinib is used in two completely different situations, and it matters which one you are in. If you have had surgery and your oncologist is now recommending osimertinib, that is adjuvant treatment — its purpose is not to treat cancer that is present and visible on scans, but to reduce the chance that microscopic disease comes back after a successful operation.
In the advanced setting, osimertinib is given when lung cancer has spread and cannot be surgically removed. It is the primary treatment there, controlling measurable disease. In the adjuvant setting, your scans are clear — the drug is working on a theoretical risk, not a visible tumour.
If someone you know is on osimertinib for stage IV lung cancer, their treatment experience will differ from yours in important ways. The duration, the monitoring schedule, and the goals of treatment are not the same.
What does taking osimertinib every day for three years involve?
Osimertinib is a tablet taken once a day, at roughly the same time each day, with or without food. You take it every day for three years — including weekends, public holidays, and days when you feel completely well.
The most common side effects are skin-related: a rash, dryness, or changes to your nails. Some people also notice loose motions, mouth sores, or reduced appetite, particularly in the first few weeks. These are manageable for most people, and your team will advise on what to do about each one.
Rare but serious reactions — including lung inflammation and heart rhythm changes — are possible. Tell your team about any new breathlessness, chest discomfort, or palpitations rather than assuming it is unrelated to the tablet.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What happens from your operation to the end of three years?
Surgery
Your operation removes the lung tumour. The surgical team sends tissue to the pathology laboratory for detailed analysis, including biomarker testing.
EGFR mutation testing
The laboratory tests your tumour tissue for EGFR mutations. Adjuvant osimertinib is recommended only if you have an exon 19 deletion or exon 21 L858R mutation. Results typically take one to two weeks.
Stage confirmed
Your oncologist reviews the full pathology report to confirm the stage. Adjuvant osimertinib is indicated for completely resected stage IB, II, and IIIA disease with the qualifying EGFR mutation.
Starting osimertinib
Once you have recovered sufficiently from surgery, your oncologist prescribes osimertinib. The timing takes your recovery and overall fitness into account.
Monitoring through treatment
You will attend clinic for blood tests and reviews throughout the three years. Your team can adjust or pause treatment if side effects require it — brief pauses do not mean treatment has failed.
Completing three years
When the course ends, osimertinib is stopped. Your team then plans a surveillance schedule with scans at agreed intervals to watch for any signs of recurrence.
Words you will hear in clinic
- Adjuvant therapy
- Treatment given after surgery when the visible tumour has been removed. The aim is to reduce the chance of the cancer returning, not to treat something currently detectable on a scan.
- EGFR mutation
- A change in the EGFR gene that drives certain lung cancers to grow. Testing for this mutation is what determines whether osimertinib is appropriate for you.
- Exon 19 deletion / exon 21 L858R
- The two specific EGFR mutations for which adjuvant osimertinib is approved. Your pathology report will name which one you have. Other EGFR mutations do not qualify for this treatment.
- Complete resection
- Surgery that removed the entire visible tumour with clear margins around it. Adjuvant osimertinib is indicated only when resection was complete — not when tumour was intentionally or inadvertently left behind.
- Disease-free survival
- The length of time after treatment during which no cancer is detected on scans or examination. This was the main outcome measured in the ADAURA trial that established the evidence for adjuvant osimertinib.
Did you know?
The ADAURA trial, which established the evidence base for adjuvant osimertinib and informed approvals by regulators including CDSCO in India, was stopped early by its independent safety monitoring committee.
The disease-free survival benefit was already so clear at the interim analysis that continuing the placebo arm was considered unjustifiable. Early halts of this kind are uncommon in oncology trials.
Source: ADAURA trial, New England Journal of Medicine 2020; NCCN Non-Small Cell Lung Cancer Guidelines
Explore 75 more Lung Cancer Targeted Medicines topics
Drug Deep Dive: Osimertinib (Tagrisso)
- Adjuvant Osimertinib After Lung Cancer Surgery: Three Years of Tablets
- Breathlessness or New Cough on Osimertinib: Recognising Lung Injury (ILD)
- Diet and Nutrition While on Osimertinib
- Drug, Food and Supplement Interactions With Osimertinib
- Fertility, Pregnancy and Contraception on Osimertinib
- Heart Rhythm and Ejection Fraction Changes on Osimertinib
- How Does Osimertinib Work? The Third-Generation EGFR Inhibitor Explained
- How Long Does Osimertinib Take to Work?
- How Long Will You Stay on Osimertinib?
- Osimertinib (Tagrisso): The Complete Patient Guide
- Osimertinib Myths: Clear Scans, Stopping Early and Generic Quality
- Osimertinib Price in India: Brand, Generic and Monthly Cost
- Osimertinib Side Effects: The Complete List and Timeline
- Osimertinib Success Rate and Survival: An Honest Look at the Numbers
- Osimertinib With Chemotherapy: Who Actually Benefits From the Combination?
- Osimertinib and Brain Metastases: Why It Works Inside the Brain
- Osimertinib in Elderly Patients and Those With Other Illnesses
- Osimertinib vs Gefitinib and Erlotinib: Is the Costlier Drug Worth It?
- Rash, Dry Skin and Nail Problems on Osimertinib
- Taking Osimertinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Osimertinib
- When Osimertinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Osimertinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Osimertinib?
- Work, Travel and Daily Life on Osimertinib
Drug Deep Dive: Alectinib (Alecensa)
- Alectinib (Alecensa, Alectinib): The Complete Patient Guide
- Alectinib After Surgery for Early-Stage ALK-Positive Lung Cancer
- Alectinib Myths: Is ALK-Positive Cancer 'Curable'?
- Alectinib Price in India: Brand, Generic and Monthly Cost
- Alectinib Side Effects: The Complete List and Timeline
- Alectinib Success Rate and Survival: An Honest Look at the Numbers
- Alectinib and Brain Metastases: How It Protects the Brain
- Alectinib in Elderly Patients and Those With Other Illnesses
- Alectinib vs Crizotinib vs Lorlatinib: Choosing an ALK Inhibitor
- Diet and Nutrition While on Alectinib
- Do You Need Chemotherapy Alongside Alectinib?
- Drug, Food and Supplement Interactions With Alectinib
- Fertility, Pregnancy and Contraception on Alectinib
- How Does Alectinib Work? The Second-Generation ALK Inhibitor Explained
- How Long Does Alectinib Take to Work?
- How Long Will You Stay on Alectinib?
- Muscle Pain and High CPK on Alectinib: When to Worry
- Severe Sun Sensitivity on Alectinib: Preventing Serious Burns
- Taking Alectinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Alectinib
- Weight Gain, Constipation and a Slow Pulse on Alectinib
- When Alectinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Alectinib? ALK-Positive Lung Cancer
- Will Insurance or a Government Scheme Pay for Alectinib?
- Work, Travel and Daily Life on Alectinib
Drug Deep Dive: Gefitinib (Iressa)
- Diarrhoea on Gefitinib: Home Management and Warning Signs
- Diet and Nutrition While on Gefitinib
- Fertility, Pregnancy and Contraception on Gefitinib
- Gefitinib (Iressa, Geftinat, Geftib): The Complete Patient Guide
- Gefitinib Myths: 'It's Only for Poor Patients' and Other Half-Truths
- Gefitinib Plus Chemotherapy: Does Adding Chemo Actually Help?
- Gefitinib Price in India: Brand, Generic and Monthly Cost
- Gefitinib Rash: Why It Appears in Week Two and How to Treat It
- Gefitinib Side Effects: The Complete List and Timeline
- Gefitinib Success Rate and Survival: An Honest Look at the Numbers
- Gefitinib and Antacids: The Interaction That Silently Reduces Absorption
- Gefitinib in Early-Stage vs Advanced Lung Cancer: Different Goals
- Gefitinib in Elderly Patients and Those With Other Illnesses
- Gefitinib vs Osimertinib: Making the Decision When Cost Matters
- How Does Gefitinib Work? The First-Generation EGFR Inhibitor Explained
- How Long Does Gefitinib Take to Work?
- How Long Will You Stay on Gefitinib?
- Raised Liver Enzymes on Gefitinib: What Your LFT Report Means
- T790M Testing After Gefitinib Stops Working: The Next Step Explained
- Taking Gefitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Gefitinib
- When Gefitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Gefitinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Gefitinib?
- Work, Travel and Daily Life on Gefitinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Why three years — why not a shorter or longer course?
Three years is the duration studied in the ADAURA trial, and it is the basis on which regulators approved adjuvant osimertinib. We do not yet have robust evidence that a shorter course provides the same protection, or that extending beyond three years adds further benefit. Your oncologist may adjust duration if significant side effects arise, but three years is the standard the evidence supports.
What happens if I miss a dose?
Take the missed dose on the same day if you remember, then continue your usual schedule the next day. Do not take two doses to make up for one missed. If you are regularly forgetting doses, tell your oncologist or pharmacist — a phone alarm or pill organiser often helps. Consistent daily use is what the evidence is based on, so the pattern over months matters more than any single day.
What side effects are most common with adjuvant osimertinib?
The most frequently reported are skin dryness, a rash on the face and upper body, nail changes, loose motions, and mouth sores. Most are manageable and do not require stopping treatment. Less commonly, people notice fatigue or reduced appetite. Rare but serious reactions — including lung inflammation and heart rhythm changes — require prompt reporting. Tell your team about any new breathlessness, significant diarrhoea, or palpitations rather than waiting for your next scheduled visit.
Do I also need chemotherapy after surgery, or does osimertinib replace it?
This depends on your stage and the details of your pathology. For some patients, adjuvant chemotherapy is also recommended and given before starting osimertinib; for others, osimertinib alone is the recommended approach. NCCN and ESMO guidance addresses both sequences. Your oncologist will explain which applies to your situation — the two treatments serve different purposes and are not mutually exclusive.
Will I need scans during the three years of treatment?
Yes. Your team will arrange CT scans at intervals during the three years to monitor for any signs of recurrence. How often depends on your centre's protocol and your stage. Blood tests at clinic reviews check your general health and watch for side effects. If a scan shows a change, your team will reassess the plan — surveillance during adjuvant treatment is part of the design, not a sign that something has gone wrong.
Does finishing three years mean the cancer is gone for certain?
Completing the course means you have received the full treatment the evidence supports for reducing recurrence risk. It does not mean recurrence is impossible — surveillance continues after osimertinib ends precisely because the risk, while reduced, does not reach zero. What the evidence shows, according to NCCN and ASCO, is that adjuvant osimertinib substantially lowers that risk compared with surgery alone in patients with the qualifying EGFR mutation. Your team will plan a post-treatment follow-up schedule as you approach the end of three years.